| Mrs Jennifer Yvette Vansandt, CRNA | |
|
2301 Holmes St, Kansas City, MO 64108-2640 | |
| (816) 440-1100 | |
| Not Available |
| Full Name | Mrs Jennifer Yvette Vansandt |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 22 Years |
| Location | 2301 Holmes St, Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114935863 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 136763 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Luke's East Hospital | Lees summit, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Lukes East Anesthesia Services,p.c. | 1850333477 | 40 |
| Cass Regional Medical Center | 7517853781 | 49 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
A new study has found that women can be screened for colorectal cancer at least five to 10 years later than men when undergoing an initial "virtual colonoscopy." Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help establish guidelines for the use of this screening technique, which is less invasive than a traditional colonoscopy.
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel - undetected by normal cells - through the bloodstream until activated by specific cancer proteins.
Scripps Research Institute scientists and their colleagues have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. Though just an initial step, the researchers hope such work will eventually lead to better understanding of how memories form in the brain, and possibly even to ways to weaken harmful thoughts for those with conditions such as schizophrenia and post traumatic stress disorder.
In observance of Heart Month in February, Vanderbilt health educator Stacey Kendrick has compiled a list of steps everyone can take for a healthier heart.
› Verified 9 days ago
| Entity Name | Cass Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477535326 PECOS PAC ID: 7517853781 Enrollment ID: O20040225000028 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
A new study has found that women can be screened for colorectal cancer at least five to 10 years later than men when undergoing an initial "virtual colonoscopy." Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help establish guidelines for the use of this screening technique, which is less invasive than a traditional colonoscopy.
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel - undetected by normal cells - through the bloodstream until activated by specific cancer proteins.
Scripps Research Institute scientists and their colleagues have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. Though just an initial step, the researchers hope such work will eventually lead to better understanding of how memories form in the brain, and possibly even to ways to weaken harmful thoughts for those with conditions such as schizophrenia and post traumatic stress disorder.
In observance of Heart Month in February, Vanderbilt health educator Stacey Kendrick has compiled a list of steps everyone can take for a healthier heart.
› Verified 9 days ago
| Entity Name | Outpatient Anesthesia Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194828673 PECOS PAC ID: 8325930803 Enrollment ID: O20040329000795 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
A new study has found that women can be screened for colorectal cancer at least five to 10 years later than men when undergoing an initial "virtual colonoscopy." Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help establish guidelines for the use of this screening technique, which is less invasive than a traditional colonoscopy.
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel - undetected by normal cells - through the bloodstream until activated by specific cancer proteins.
Scripps Research Institute scientists and their colleagues have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. Though just an initial step, the researchers hope such work will eventually lead to better understanding of how memories form in the brain, and possibly even to ways to weaken harmful thoughts for those with conditions such as schizophrenia and post traumatic stress disorder.
In observance of Heart Month in February, Vanderbilt health educator Stacey Kendrick has compiled a list of steps everyone can take for a healthier heart.
› Verified 9 days ago
| Entity Name | Saint Lukes Hospital Of Chillicothe |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245433127 PECOS PAC ID: 0143130393 Enrollment ID: O20041014000548 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
A new study has found that women can be screened for colorectal cancer at least five to 10 years later than men when undergoing an initial "virtual colonoscopy." Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help establish guidelines for the use of this screening technique, which is less invasive than a traditional colonoscopy.
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel - undetected by normal cells - through the bloodstream until activated by specific cancer proteins.
Scripps Research Institute scientists and their colleagues have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. Though just an initial step, the researchers hope such work will eventually lead to better understanding of how memories form in the brain, and possibly even to ways to weaken harmful thoughts for those with conditions such as schizophrenia and post traumatic stress disorder.
In observance of Heart Month in February, Vanderbilt health educator Stacey Kendrick has compiled a list of steps everyone can take for a healthier heart.
› Verified 9 days ago
| Entity Name | St Lukes East Anesthesia Services,p.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649283177 PECOS PAC ID: 1850333477 Enrollment ID: O20050524001050 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
A new study has found that women can be screened for colorectal cancer at least five to 10 years later than men when undergoing an initial "virtual colonoscopy." Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help establish guidelines for the use of this screening technique, which is less invasive than a traditional colonoscopy.
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel - undetected by normal cells - through the bloodstream until activated by specific cancer proteins.
Scripps Research Institute scientists and their colleagues have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. Though just an initial step, the researchers hope such work will eventually lead to better understanding of how memories form in the brain, and possibly even to ways to weaken harmful thoughts for those with conditions such as schizophrenia and post traumatic stress disorder.
In observance of Heart Month in February, Vanderbilt health educator Stacey Kendrick has compiled a list of steps everyone can take for a healthier heart.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jennifer Yvette Vansandt, CRNA 5700 Ne Misty Meadow Way, Lees Summit, MO 64064-1285 Ph: (816) 373-0250 | Mrs Jennifer Yvette Vansandt, CRNA 2301 Holmes St, Kansas City, MO 64108-2640 Ph: (816) 440-1100 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
A new study has found that women can be screened for colorectal cancer at least five to 10 years later than men when undergoing an initial "virtual colonoscopy." Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help establish guidelines for the use of this screening technique, which is less invasive than a traditional colonoscopy.
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel - undetected by normal cells - through the bloodstream until activated by specific cancer proteins.
Scripps Research Institute scientists and their colleagues have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. Though just an initial step, the researchers hope such work will eventually lead to better understanding of how memories form in the brain, and possibly even to ways to weaken harmful thoughts for those with conditions such as schizophrenia and post traumatic stress disorder.
In observance of Heart Month in February, Vanderbilt health educator Stacey Kendrick has compiled a list of steps everyone can take for a healthier heart.
› Verified 9 days ago
Michael S Filla, RN, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2316 E Meyer Blvd, Kansas City, MO 64132 Phone: 816-276-4000 | |
Kelli A Pryor, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-1100 | |
Sydney L. Overton, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2316 E Meyer Blvd, Kansas City, MO 64132 Phone: 816-763-5446 Fax: 816-763-8426 | |
Adrienne Jill Rader, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2316 E Meyer Blvd, Kansas City, MO 64132 Phone: 816-763-5446 Fax: 816-763-8426 | |
Jon R Featherston, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-1100 | |
Daniel E Roberson, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3000 Fax: 816-302-9939 | |
Dr. Vanessa Rae Jackson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 721 Ne 82nd Ter, Kansas City, MO 64118 Phone: 816-646-1242 |